SARS-CoV-2 is one of the infectious agents that cause severe acute respiratory syndrome disease. SARS-CoV-2 is an RNA virus of which SARS and MERS are also part. It is a virus that infects a person when it binds to the receptor for angiotensin converting enzyme 2 (ACE2) and therefore penetrates its target cell. This receptor binds to the enzyme. It is involved in a number of effects such as: regulation of high blood pressure, diabetic nephropathy and congestive heart failure. This receptor is ubiquitous in many cells (lung AT2 cells, respiratory epithelial cells, myocardial cells, cells of the esophagus and ileum, cells of the proximal tube of the kidney, and urothelial cells of the bladder). This can be one of the causes of this spread in the body. For this purpose, the virus uses its surface Glycoprotein S. The virus could use the ACE2 pathway to enter cells and enhance their infectivity. The use of various conventional therapies for the COVID-19 coronavirus, such as ACE2 receptor agonists, and also hydroxychloroquine, are currently being contemplated with different results depending on the type of patient. This communication presents a medicinal alternative derived from a plant that has been documented in the past. Hibiscosabdariffa, a tropical plant that receives several generic names: Flor de Jamaica, Roselle, among others. This plant has been the subject of phytochemical studies that have led to several results on its medicinal properties. They have been found to have the ability to target the AEC2 receptor with agonistic properties and also have a number of chemical compounds that have a structural similarity to hydroxychloroquine (rutin and anthocyanin). In addition, it has structures similar to mannose compounds that could bind to MLB receptors also agonistically (protocatechuic acid)